The forecast for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) medicine sales in Canada shows a declining trend from 2024 to 2028, with a decrease from $16.7 to $15.7 US dollars per capita. Comparing each year, the year-on-year decrease is evident with incremental reductions in value. The average annual decline calculated over this five-year period offers a clear overview of a downward trajectory.

Future trends to watch for include:

Potential innovations in treatment, which could influence sales if newer, more effective options become available.
Shifts in healthcare policies and funding that may impact medication accessibility and consumption levels.
Increasing public awareness and lifestyle changes that could reduce the prevalence of these conditions, further affecting demand.